Abstract：New York-based AI chemistry company Excelsior Sciences recently completed a $95 million financing round. The funds will be used to advance its "intelligent module" technology, accelerating the discovery and production of small molecule drugs. The company aims to address long-standing industry challenges such as low R&D efficiency and reliance on offshore manufacturing through a novel machine-executable chemical system, while also responding to the demand for reshoring the U.S. pharmaceutical supply chain.Behind the Financing: Giants and Academic Institutions Join Hands to Place Bets
On December 3, Excelsior Sciences disclosed in an official statement that the $95 million funding round was composed of two parts: a $70 million Series A financing and a $25 million government grant. The Series A financing was co-led by healthcare investment giant Deerfield Management, venture capital firms Khosla Ventures and Sofinnova Partners, with participation from industry capital including Eli Lilly and Cornucopian Capital, as well as academic institutions such as MIT; the $25 million grant came from the New York State Empire Development Agency, specifically to support the company’s technology implementation and local production capacity building.Notably, the involvement of Eli Lilly and Company is no coincidence. Just a month ago, the pharmaceutical giant announced a collaboration exceeding $100 million with Insilico Medicine, an AI-driven drug discovery company. This latest investment in Excelsior Sciences further underscores the growing interest of major pharmaceutical firms in the “AI + small molecule” space. Additionally, the participation of MIT provides academic endorsement for the company’s technological development.Core Breakthrough: Using "Smart Modules" to Solve Automation Challenges
"Chemical automation in the past has been mimicking manual operations, which is a dead end," said Dr. Michael Foley, CEO of Excelsior Sciences, Inc., in an interview. In traditional small molecule drug development, each molecule requires a customized synthesis process, with experiments often spanning multiple labs across the U.S. and Asia, taking over four months and incurring extremely high costs.The company's solution is "Smart Bloccs" technology — a type of chemically synthesizable building block that can be automated. These modules can be pieced together like Lego bricks to form stable carbon-carbon bonds. More importantly, they can act as a "chemical language" recognizable by AI. By analyzing module combination data, AI can quickly predict the optimal R&D pathway, forming a closed loop of "design-synthesis-testing."According to Jim Flynn, Managing Partner of Deerfield, with this system, the experimental process that originally took four months can be compressed to two weeks, and the subsequent production phase can reuse the same process, saving one to eighteen months before clinical trials alone.Targeting the Pain Points: Fast R&D and Supply Chain Security Are Both Essential
The U.S. pharmaceutical industry is currently facing dual pressures: On one hand, small-molecule drugs account for 60% of FDA newly approved drugs, but their R&D cycle often exceeds 10 years and costs billions of dollars. On the other hand, U.S. drug manufacturing is highly dependent on offshore outsourcing, with geopolitical fluctuations frequently threatening supply chain security. The industry has committed to investing $250 billion to address this issue.Excelsior's technology happens to address these two major pain points simultaneously. In addition to accelerating R&D, the company also plans to lower the threshold for domestic manufacturing through the standardized production of "intelligent modules." Hope Knight, President of the New York State Empire Development Agency, stated that supporting Excelsior is not only about promoting AI chemical technology but also about "making New York the core of China's domestic pharmaceutical supply chain to ensure the safety of pharmaceuticals in the United States."As planned, Excelsior will demonstrate the operational effectiveness of the complete platform within 12 months and apply it to at least one drug development project. In the future, its technology may also extend to fields such as materials science and veterinary drugs, becoming a cross-industry AI chemistry solutions provider.Reference source: https://www.fiercepharma.com/manufacturing/ai-chemistry-outfit-excelsior-collects-95m-mission-accelerate-discovery-production
Scan the WeChat QR code, add the editor of the Biological Products Circle, and those who meet the requirements can join.
Biological Products WeChat Group!
Please indicate: Name + Research Direction!All reproduced articles in this official account are intended to convey more information, with the source and author clearly stated. Media or individuals who do not wish to be reprinted can contact us (cbplib@163.com), and we will immediately delete the content. All articles represent the views of the author and not this site.
